Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12454
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZwan, M D-
dc.contributor.authorOkamura, N-
dc.contributor.authorFodero-Tavoletti, Michelle T-
dc.contributor.authorFurumoto, S-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorVillemagne, Victor L-
dc.date.accessioned2015-05-16T02:09:17Z
dc.date.available2015-05-16T02:09:17Z
dc.date.issued2014-10-31-
dc.identifier.citationThe Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (aimn) [and] the International Association of Radiopharmacology (iar), [and] Section of the Society of Radiopharmaceutica 2014; 58(4): 398-412en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12454en
dc.description.abstractThe last decade has witnessed the development and characterization of tracers for the evaluation of neuropathology in vivo. The introduction of these tracers, namely β-amyloid (Aβ) and later tau, are providing the tools to change the landscape and refine our understanding of Aβ and tau deposition in the brain, allowing to investigate the causes, refine diagnosis and improve treatment of major neurodegenerative conditions such as Alzheimer's disease (AD), chronic traumatic encephalopathy (CTE) and frontotemporal lobar degeneration (FTLD). Aβ and tau imaging allow examination of the regional and global changes of these disease markers over time as well as their relationship with other relevant parameters such as cognitive performance and neurodegenerative changes. Aβ and tau imaging will enable to establish the role Aβ and tau play -and interplay- in aging and disease. Aβ and tau imaging value resides in being not only diagnostic, prognostic or progression markers, but also surrogate markers of disease, crucial for patient recruitment and efficacy evaluation of disease-specific therapies.en
dc.language.isoenen
dc.titleVoyage au bout de la nuit: Aβ and tau imaging in dementias.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biologyen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET Austin Health, Heidelberg, Victoria, Australia -en
dc.description.pages398-412en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25358680en
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherMasters, Colin L
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Sep 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.